Drug Profile
Zelavespib - Samus Therapeutics
Alternative Names: PU-H-71; Purine-scaffold HSP90 inhibitor - Samus TherapeuticsLatest Information Update: 27 Jan 2023
Price :
$50
*
At a glance
- Originator Memorial Sloan-Kettering Cancer Center
- Developer Memorial Sloan-Kettering Cancer Center; National Cancer Institute (USA); Samus Therapeutics
- Class Amines; Antineoplastics; Benzodioxoles; Iodinated hydrocarbons; Organic sulfur compounds; Purines; Small molecules
- Mechanism of Action HSP90 heat-shock protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Myelofibrosis
- Preclinical Acute myeloid leukaemia
- No development reported Breast cancer; Lymphoma; Solid tumours
- Discontinued Non-Hodgkin's lymphoma
Most Recent Events
- 10 Dec 2022 Adverse events data from a phase I trial in Myelofibrosis presented at the 64th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2022)
- 28 Nov 2022 Samus Therapeutics terminates phase I trial in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (Post-PV MF), and post-essential thrombocytopenia myelofibrosis (Post-ET MF) who are receiving ruxolitinib in the US (NCT03935555)
- 14 Nov 2022 Phase-I development is ongoing for Myelofibrosis (Treatment-experienced) in USA (PO) (NCT03935555)